The Outcomes of Concomitant Radiation Plus Temozolomide ... - NCI

118
The Outcomes of Concomitant Radiation Plus Temozolomide
patients with newly diagnosed glioblastoma
multiforme treated with concomitant radiation plus
temozolomide followed by adjuvant temozolomide.
J Clin Oncol. 2002, 20 (5): 1375- 82.
44- Mirimanoff RO, Gorlia T, Mason W, Van den Bent
MJ, Kortmann RD, Fisher B, et al. Radiotherapy and
Temozolomide for Newly Diagnosed Glioblastoma:
Recursive Partitioning Analysis of the EORTC
26981/22981-NCIC CE3 Phase III Randomized Trial.
J. Clin. Oncol. 2006, 24 (16): 2563-9.
45- Macdonald DR, Cascino TL, Schold SC Jr, Cairncross
JG. Response criteria for phase II studies of supratentorial
malignant glioma. J Clin Oncol. 1990, 8: 1277-80.
46- Kaplan EL, Meier P. Nonparametric estimation from
incomplete observations. J Am Stat Assoc. 1958, 53:
457-81.
47- Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme
I, Nesbakken R, et al. Combined modality therapy of
operated astrocytomas grade III and IV: Confirmation
of the value of postoperative irradiation and lack of
potentiation of bleomycin on survival time-A
prospective multicenter trial of the Scandinavian
Glioblastoma Study Group. Cancer. 1981, 47: 649-
52.
48- Shapiro WR. Chemotherapy of malignant gliomas:
studies of the BTCG. Rev Neurol. 1992, 148: 428-
34.
49- Grossman SA, O'Neill A, Grunnet M, Mehta M,
Pearlman JL, Wagner H, et al. Phase III study
comparing three cycles of infusional carmustine and
cisplatin followed by radiation therapy with radiation
therapy and concurrent carmustine in patients with
newly diagnosed supratentorial glioblastoma
multiforme: Eastern Cooperative Oncology Group
Trial 2394. J Clin Oncol. 2003, 21: 1485-91.
50- Deutsch M, Green SB, Strike TA, Burger PC,
Robertson JT, Selker RG, et al. Results of a randomized
trial comparing BCNU plus radiotherapy,
streptozotocin plus radiotherapy, BCNU plus
hyperfractionated radiotherapy, and BCNU following
misonidazole plus radiotherapy in the postoperative
treatment of malignant glioma. Int J Radiat Oncol
Biol Phys. 1989, 16: 1389-96.
51- Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran
WJ. Phase I study of topotecan plus cranial radiation
for glioblastoma multiforme: Results of Radiation
Therapy Oncology Group Trial 9507. J Clin Oncol.
2001, 19: 1111-7.
52- Del Rowe J, Scott C, Werner-Wasik M, Bahary JP,
Curran WJ, Urtasun RC, et al. Single-arm, open-label
phase II study of intravenously administered
tirapazamine and radiation therapy for glioblastoma
multiforme. J Clin Oncol. 2000, 18: 1254-9.
53- Kleinberg L, Grossman SA, Piantadosi S, Zeltzman
M, Wharam M. The effects of sequential versus
concurrent chemotherapy and radiotherapy on survival
and toxicity in patients with newly diagnosed highgrade
astrocytoma. Int J Radiat Oncol Biol Phys.
1999, 44: 535-43.
54- Brem H, Piantadosi S, Burger PC, Walker M, Selker
R, Vick NA, et al. Placebo-controlled trial of safety
and efficacy of intraoperative controlled delivery by
biodegradable polymers of chemotherapy for recurrent
gliomas: The Polymer-Brain Tumor Treatment Group.
Lancet. 1995, 345: 1008-12.
55- Westphal M, Hilt DC, Bortey E, Delavault P, Olivares
R, Warnke PC, et al. A phase 3 trial of local
chemotherapy with biodegradable carmustine (BCNU)
wafers (Gliadel wafers) in patients with primary
malignant glioma. Neuro-Oncology. 2003, 5 (2): 79-
88.
56- Friedman HS, Kerby T, Calvert H. Temozolomide and
treatment of malignant glioma. Clin Cancer Res. 2000,
6: 2585-97.
57- Reid JM, Stevens DC, Rubin J, Ames MM.
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-
4-carboximide following administration of
temozolomide to patients with advanced cancer. Clin
Cancer Res. 1997, 3: 2393-8.
58- van den Bent MJ, Taphoorn MJB, Brandes AA, Menten
J, Stupp R, Frenay M, et al. Phase II Study of First-
Line Chemotherapy With Temozolomide in Recurrent
Oligodendroglial Tumors: The European Organization
for Research and Treatment of Cancer Brain Tumor
Group Study 26971. J. Clin. Oncol. 2003, 21 (13):
2525-8.
59- Newlands ES, Stevens MFG, Wedge SR, Wheelhouse
RT, Brock C. Temozolomide: a review of its discovery,
chemical properties, pre-clinical development and
clinical trials. Cancer Treat Rev. 1997, 23: 35-61.
60- Stupp R, Gander M, Leyvraz S, Newlands E. Current
and future developments in the use of temozolomide
for the treatment of brain tumours. Lancet Oncol,
2001;2: 552 - 60.
61- Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA,
Abrey LE. A phase II study of extended low-dose
temozolomide in recurrent malignant gliomas. Neurooncol.
2002, 4 (1): 39 - 43.
62- Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS,
Brada M, Friedman HS, et al. Multicenter phase II
trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first
relapse. J Clin Oncol. 1999, 17 (9): 2762- 71.
63- Yung WK, Albright RE, Olson J, Fredericks R, Fink
K, Prados MD, et al. A phase II study of temozolomide
vs. procarbazine in patients with glioblastoma
multiforme at first relapse. Br J Cancer. 2000, 83:
588- 93.
64- Brada M, Hoang-Xuan K, Rampling R, Dietrich P-Y,
Dirix LY, Macdonald D, et al. Multicenter phase II
trial of temozolomide in patients with glioblastoma
multiforme at first relapse. Ann Oncol. 2001, 12: 259-
66.
65- Kocher M, Kunze S, Eich HT, Semrau R, Muller RP.
Efficacy and toxicity of postoperative temozolomide
radiochemotherapy in malignant glioma. Strahlenther
Onkol. 2005, 181: 157-63.